Back to News
Market Impact: 0.25
UBS Upgrades Illumina to Buy from Neutral
Source: Nasdaq
Analyst InsightsHealthcare & Biotech
UBS upgraded Illumina (NASDAQGS: ILMN) to Buy from Neutral on September 9, 2026, reversing its prior Neutral stance maintained on October 31, 2025. The analyst-rating improvement is a modest positive catalyst for the genomics company, though the article provides no price target, earnings estimates, or operating rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ILMN0.55
UBS0.00
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth?
- How Pepsi fell behind in the cola wars—and then lost KFC
- 5 big analyst AI moves: ’Uniquely catalyst-rich’ months ahead for SpaceX
- Xencor reports phase 1 data for cancer drug XmAb819
- UK immigration crackdown threatens £15 billion care sector